Ultrasound boosts steroid cream for vitiligo in new trial
NCT ID NCT07267273
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests if using ultrasound (phonophoresis) to push betamethasone cream deeper into the skin can help control vitiligo, a condition that causes white patches. Researchers will enroll 60 adults with vitiligo who are otherwise healthy. The goal is to see if this approach reduces the visibility of patches, but it is not a cure—ongoing treatment is expected.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2025
- Expected to finish
-
Feb 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
25 to 40 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Male and female patients diagnosed with vitiligo. * Medically and psychologically stable patients. * Good cognitive abilities to understand the requirements of the study. * All patients enrolled to the study will have their informed consent. * they had no contraindications to the use of therapeutic ultrasound Exclusion Criteria: * Pregnancy or lactation. * Immunosuppression. * Alcohol abuse. * History of spontaneous re-pigmentation of lesions. * Presence of skin characteristics that may interfere with study assessment. * Active bacterial/viral infection. * Patients on other immune suppressants and phototherapy * Patients currently participating in any other clinical study * Uncooperative patients.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Vitiligo are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Cairo University Hospital
RECRUITINGCairo, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a skin cream bring back color to faces with vitiligo?
- Skin markers may reveal how light therapy fights vitiligo
- Can Real-World data unlock better skin disease care?
- New ointment aims to restore skin color in vitiligo
- Skin microbes linked to vitiligo and immunotherapy reactions in melanoma patients
- New vitiligo registry aims to uncover disease trends in 2,500 patients